-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The National Pharmaceutical Economic Information Conference Kicks Off | Shijiazhuang Sihua Pharmaceutical Group Honored with the Prestigious Title of “Leading Force” in China’s High-Quality Pharmaceutical Development for 2022
Category:
Time：2023-02-21
In early spring, Zhuhai, Guangdong Province—located in the Guangdong-Hong Kong-Macao Greater Bay Area—is awash with colorful flowers, radiating vitality and生机. On the evening of February 19, the "2022 Comprehensive Review of High-Quality Development in the Pharmaceutical Industry: Identifying Leading Forces in a Multipolar Track"—one of the series of events for the 34th National Pharmaceutical Economic Information Conference, hosted by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and organized by the Pharmaceutical Economic Daily—was solemnly announced. Shijiazhuang Four Pharmaceutical Group was honored with the titles of “2022 Leading Force—China’s High-Quality Pharmaceutical Development Achievement Enterprise (Strong Company)” and “Achievement Brand—Yibedi Brand Cefdinir Capsules.”
In early spring, Zhuhai, Guangdong Province—located in the Guangdong-Hong Kong-Macao Greater Bay Area—is awash with colorful flowers and brimming with vitality. On the evening of February 19, the “2022 Comprehensive Review of High-Quality Development in the Pharmaceutical Industry: Identifying Leading Forces in a Multipolar Track,” one of the series of events for the 34th National Pharmaceutical Economic Information Conference, organized by the Southern Institute of Pharmaceutical Economics under the National Medical Products Administration and hosted by Pharmaceutical Economic News, was solemnly announced. Shijiazhuang Four Pharmaceutical Group was honored with two prestigious awards for its outstanding contributions to China’s high-quality pharmaceutical development in 2022: “Leading Force—China’s High-Quality Pharmaceutical Development Achievement Enterprise (Strong Company)” and “Achievement Brand—Yibedi Brand Cefdinir Capsules.”
Focusing on the present moment, the post-pandemic global upheaval is ushering in a new stable state for China’s pharmaceutical economy: total scale continues to grow steadily, profit drivers are diversifying and being restructured, the regulatory framework is gradually improving, regulatory capacity has significantly strengthened, standards are being upgraded to align with international norms, cutting-edge innovation is closely linked to the global community, catalog adjustments are being rolled out in stages, volume-based procurement has become the new norm, competitive order is constantly being refined, terminal market dynamics are intensifying amid both competition and collaboration, and the potential benefits from essential medicine demand are promising. This is a new era of upholding integrity while fostering innovation and moving forward with courage and determination—a fresh starting point marked by unity of purpose and shared momentum. The Southern Institute of the National Medical Products Administration is focusing on the leading forces driving industrial development, taking it as its mission to highlight the resilience and vitality of the pharmaceutical industry, illuminate the path of persistent advancement, unlock the potential for industrial upgrading, and strive to establish a benchmark that sets a new standard for the industry.
In 2022, guided by the Healthy China initiative, the pharmaceutical industry leveraged innovation to drive development, continuously focusing on cutting-edge areas and attracting innovative resources. A number of outstanding enterprises in the industry are now emerging as new pioneers, practitioners, and leaders in China’s pharmaceutical sector. Shijiazhuang Fourth Pharmaceutical Group, as an exemplary representative, has strategically aligned its innovation chain with the industrial value chain. The group maintains a leading position in the industry in terms of both the number of approved and filed generic drug development projects, and its innovation-driven approach continues to propel the company toward the mid-to-high end of the industry, making it a key force behind the growth of top-tier enterprises in the sector.
It is reported that the 2022 China Pharmaceutical Industry’s “Leading Forces” selection for High-Quality Development, evaluated across dimensions such as “international recognition, operational stability index, performance indicators, and social responsibility index,” was conducted through multiple rounds of rigorous selection, aiming to recognize industry leaders who remain true to their original aspirations and continue forging ahead.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license